Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Aldurazyme | Laronidase | Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie | Do not list | Complete | ||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
| Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
| VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
| Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete |
Last Updated : May 14, 2024